FOR IMMEDIATE RELEASE

Celgene’s Revlimid® Patents Do Not Withstand Review

CHARLOTTESVILLE, VA – On May 7, 2015, the European Patent Office revoked one of Celgene’s (NASDAQ: CELG) patents on Revlimid®. Revlimid® reportedly accounts for almost $5 billion of Celgene’s nearly $7.5 billion in annual revenue and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer and other autoimmune diseases.

A systematic and rigorous review of the available precedent information, undertaken by M·CAM, provides a sound basis for the invalidation of many other Revlimid® patents, including those currently listed in the FDA’s Orange Book, on the grounds that they are based on an older drug and that the use of the drug in the treatment of cancer was obvious. If the invalidation of the entire Revlimid® portfolio were systematically pursued by a third party, it could materially and adversely impact Celgene.

Simply put, the core Revlimid® compound patent, U.S. Pat. No. 5,635,517 (‘517), is and has always been based on an old drug (thalidomide) and the “innovations” on which Revlimid is based, going back to its priority date in 1996, are obvious in light of precedent innovation. As a result, the ‘517 patent should not be entitled to patent protection in the United States or any of the nearly 70 countries where Revlimid® is approved. Since this base patent of the Revlimid® families of patents is not valid, then many of the Revlimid® patents are subject to validity or commercial relevance challenges.

The full report can be found at Harvest Exchange.

About M·CAM

M·CAM is a global financial institution that advises corporations and investors on corporate finance and asset allocation by underwriting intellectual property (IP) and intangible assets (IA). From its roots in providing financial products enabling lenders to use IP and IA as regulatory acceptable collateral for lending, M·CAM’s capital solutions address the financial needs of businesses and investors in the Knowledge Economy. M·CAM has been providing capital markets solutions to financial, sovereign, and corporate institutions since its inception in 1998.

contact@m-cam.com
210 Ridge-McIntire Road
Charlottesville, VA 22902
www.m-cam.com
434-979-7240